Unresectable hepatocellular carcinoma: Survival and prognostic factors after lipiodol chemoembolisation in 89 patients

Digestive and Liver Disease

Volumn 38, Issue 2, 2006, Pages 125-133

  Dumortier, J ^a   Chapuis, F ^b   Borson, O ^a   Davril, B ^a   Scoazec, J Y ^a   Poncet, G ^a   Henry, L ^a   Boillot, O ^a   Mion, F ^a   Berger, F ^a   Partensky, C ^a   Paliard, P ^a   Valette, P J ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b Clinical Epidemiology Unit   (France)

Author keywords

Chemoembolisation; Hepatocellular carcinoma; Lipiodol; Prognostic factors; Survival

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; BILIRUBIN; DOXORUBICIN; GELATIN SPONGE; IODINATED POPPYSEED OIL; LIPIODOL ULTRAFLUIDE; SERUM ALBUMIN; ANTINEOPLASTIC ANTIBIOTIC; CONTRAST MEDIUM;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANALYTICAL PARAMETERS; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CLASSIFICATION; CANCER SIZE; CHEMOEMBOLIZATION; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CONTRAST MEDIA; DOXORUBICIN; FEMALE; HUMANS; INJECTIONS, INTRA-ARTERIAL; IODIZED OIL; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 33745430301     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2005.10.025     Document Type: Article

References (50)

1. Okuda K., Ohtsuki T., Obata H., Tomimatsu M., Okazaki N., Hasegawa H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56 (1985) 918-928
2. Rose A.T., Rose D.M., Pinson C.W., Wright J.K., Blair T., Blanke C., et al. Hepatocellular carcinoma outcomes based on indicated treatment strategy. Am Surg 64 (1998) 1128-1135
3. Livraghi T., Bolondi L., Buscarini L., Cottone M., Mazziotti A., Morabito A., et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. J Hepatol 22 (1995) 522-526
4. Ohnishi K., Yoshioka H., Ito S., and Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 27 (1998) 67-72
5. Allgaier H.P., Deibert P., Zuber I., Olschewski M., and Blum H.E. Percutaneous radiofrequency interstitial thermal ablation of small hepatocellular carcinoma [letter]. Lancet 353 (1999) 1676-1677
6. Yamashita Y., Takahashi M., Koga Y., Saito R., Nanakawa S., Hatanaka Y., et al. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. Cancer 67 (1991) 385-391
7. Vetter D., Wenger J.J., Bergier J.M., Doffoel M., and Bockel R. Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a Western comparative study in 60 patients. Hepatology 13 (1991) 427-433
8. Bismuth H., Morino M., Sherlock D., Castaing D., Miglietta C., Cauquil P., et al. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg 163 (1992) 387-394
9. Aoyama K., Tsukishiro T., Okada K., Tsuchida T., Aiba N., Nambu S., et al. Evaluation of transcatheter arterial embolization with epirubicin-lipiodol emulsion for hepatocellular carcinoma. Cancer Chemother Pharmacol 31 Suppl. (1992) S55-S59
10. Bronowicki J.P., Vetter D., Dumas F., Boudjema K., Bader R., Weiss A.M., et al. Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer 74 (1994) 16-24
11. Bruix J., Castells A., Montanya X., Calvet X., Bru C., Ayuso C., et al. Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology 20 (1994) 643-650
12. Nakamura H., Mitani T., Murakami T., Hashimoto T., Tsuda K., Nakanishi K., et al. Five-year survival after transcatheter chemoembolization for hepatocellular carcinoma. Cancer Chemother Pharmacol 33 Suppl. (1994) S89-S92
13. Rose D.M., Chapman W.C., Brockenbrough A.T., Wright J.K., Rose A.T., Meranze S., et al. Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma. Am J Surg 177 (1999) 405-410
14. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332 (1995) 1256-1261
15. Llovet J.M., Real M.I., Montana X., Planas R., Coll S., Aponte J., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002) 1734-1739
16. Akashi Y., Koreeda C., Enomoto S., Uchiyama S., Mizuno T., Shiozaki Y., et al. Prognosis of unresectable hepatocellular carcinoma: an evaluation based on multivariate analysis of 90 cases. Hepatology 14 (1991) 262-268
17. Ikeda K., Kumada H., Saitoh S., Arase Y., and Chayama K. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model. Cancer 68 (1991) 2150-2154
18. Hatanaka Y., Yamashita Y., Takahashi M., Koga Y., Saito R., Nakashima K., et al. Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management. Radiology 195 (1995) 747-752
19. Pelletier G., Roche A., Ink O., Anciaux M.L., Derhy S., Rougier P., et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11 (1990) 181-184
20. Mondazzi L., Bottelli R., Brambilla G., Rampoldi A., Rezakovic I., Zavaglia C., et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology 19 (1994) 1115-1123
21. Chlebowski R.T., Tong M., Weissman J., Block J.B., Ramming K.P., Weiner J.M., et al. Hepatocellular carcinoma. Diagnostic and prognostic features in North American patients. Cancer 53 (1984) 2701-2706
22. Stuart K., Stokes K., Jenkins R., Trey C., and Clouse M. Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization. Cancer 72 (1993) 3202-3209
23. Stuart K.E., Anand A.J., and Jenkins R.L. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 77 (1996) 2217-2222
24. Rosellini S.R., Arienti V., Nanni O., Ugenti F., Tassinari M., Camporesi C., et al. Hepatocellular carcinoma. Prognostic factors and survival analysis in 135 Italian patients. J Hepatol 16 (1992) 66-72
25. Farinati F., De Maria N., Marafin C., Herszenyi L., Del Prato S., Rinaldi M., et al. Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. Dig Dis Sci 41 (1996) 2332-2339
26. Nakamura H., Hashimoto T., Oi H., and Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 170 (1989) 783-786
27. Hsieh M.Y., Chang W.Y., Wang L.Y., Chen S.C., Chuang W.L., Lu S.N., et al. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization and analysis of prognostic factors. Cancer Chemother Pharmacol 31 Suppl. (1992) S82-S85
28. Yamamoto K., Masuzawa M., Kato M., Okuyama T., and Tamura K. Analysis of prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization. Cancer Chemother Pharmacol 31 Suppl. (1992) S77-S81
29. Okada S., Shimada K., Yamamoto J., Takayama T., Kosuge T., Yamasaki S., et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 106 (1994) 1618-1624
30. Calvet X., Bruix J., Gines P., Bru C., Sole M., Vilana R., et al. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology 12 (1990) 753-760
31. Attali P., Prod'Homme S., Pelletier G., Papoz L., Ink O., Buffet C., et al. Prognostic factors in patients with hepatocellular carcinoma. Attempts for the selection of patients with prolonged survival. Cancer 59 (1987) 2108-2111
32. Takayasu K., Wakao F., Moriyama N., Muramatsu Y., Yamazaki S., Kosuge T., et al. Postresection recurrence of hepatocellular carcinoma treated by arterial embolization: analysis of prognostic factors. Hepatology 16 (1992) 906-911
33. Falkson G., Cnaan A., Schutt A.J., Ryan L.M., and Falkson H.C. Prognostic factors for survival in hepatocellular carcinoma. Cancer Res 48 (1988) 7314-7318
34. Okada S., Okazaki N., Nose H., Yoshimori M., and Aoki K. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology 16 (1992) 112-117
35. Llado L., Virgili J., Figueras J., Valls C., Dominguez J., Rafecas A., et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 88 (2000) 50-57
36. Takayasu K., Suzuki M., Uesaka K., Muramatsu Y., Moriyama N., Yoshida T., et al. Hepatic artery embolization for inoperable hepatocellular carcinoma; prognosis and risk factors. Cancer Chemother Pharmacol 23 Suppl. (1989) S123-S125
37. Lee H.S., Kim J.S., Choi I.J., Chung J.W., Park J.H., and Kim C.Y. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer 79 (1997) 2087-2094
38. Savastano S., Miotto D., Casarrubea G., Teso S., Chiesura-Corona M., and Feltrin G.P. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol 28 (1999) 334-340
39. Hsieh M.Y., Lu S.N., Wang L.Y., Liu T.Y., Su W.P., Lin Z.Y., et al. Alpha-fetoprotein in patients with hepatocellular carcinoma after transcatheter arterial embolization. J Gastroenterol Hepatol 7 (1992) 614-617
40. Barbara L., Benzi G., Gaiani S., Fusconi F., Zironi G., Siringo S., et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 16 (1992) 132-137
41. Chapel F., Guettier C., Chastang C., Rached A.A., Mathieu D., Tepper M., et al. Needle biopsy of hepatocellular carcinoma: assessment of prognostic contribution of histologic parameters including proliferating cell nuclear antigen labeling and correlations with clinical outcomes. Cancer 77 (1996) 864-871
42. Shijo H., Okazaki M., Higashihara H., Koganemaru F., and Okumura M. Hepatocellular carcinoma: a multivariate analysis of prognostic features in patients treated with hepatic arterial embolization. Am J Gastroenterol 87 (1992) 1154-1159
43. Ernst O., Sergent G., Mizrahi D., Delemazure O., Paris J.C., and L'Hermine C. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. Am J Roentgenol 172 (1999) 59-64
44. Vogl T.J., Trapp M., Schroeder H., Mack M., Schuster A., Schmitt J., et al. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center. Radiology 214 (2000) 349-357
45. Kanematsu T., Furuta T., Takenaka K., Matsumata T., Yoshida Y., Nishizaki T., et al. A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology 10 (1989) 98-102
46. Choi B.I., Kim H.C., Han J.K., Park J.H., Kim Y.I., Kim S.T., et al. Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings. Radiology 182 (1992) 709-713
47. Imaeda T., Yamawaki Y., Seki M., Goto H., Iinuma G., Kanematsu M., et al. Lipiodol retention and massive necrosis after lipiodol-chemoembolization of hepatocellular carcinoma: correlation between computed tomography and histopathology. Cardiovasc Intervent Radiol 16 (1993) 209-213
48. Higuchi T., Kikuchi M., and Okazaki M. Hepatocellular carcinoma after transcatheter hepatic arterial embolization. A histopathologic study of 84 resected cases. Cancer 73 (1994) 2259-2267
49. Park C., Choi S.I., Kim H., Yoo H.S., and Lee Y.B. Distribution of lipiodol in hepatocellular carcinoma. Liver 10 (1990) 72-78
50. Bhattacharya S., Dhillon A.P., Winslet M.C., Davidson B.R., Shukla N., Gupta S.D., et al. Human liver cancer cells and endothelial cells incorporate iodised oil. Br J Cancer 73 (1996) 877-881